BDNF Archives

Promising Results of Preclinical Study of ANAVEX®2-73

Holly Roos Research Updates August 26, 2021August 26, 2021Alzheimer's, autism, BDNF, cancer, FRAXA-DVI, Rett syndrome, seizure

We are excited to share that Anavex Life Sciences announced today that preclinical data of the ANAVEX®2-73 (blarcamesine) study in Fragile X syndrome were published in the peer-reviewed journal, Scientific Reports.

Coffee, Tea, and Chocolate: Adenosine Receptors in Fragile X

FRAXA Research Foundation 2018 Grants • 2019 Grants • 2020 Grants • 2021 Grants • Borreca, Antonella • Completed Research Grants • Disease Mechanisms • Italian National Institute of Health • Martire, Alberto • Treatment Targets December 11, 2018April 5, 2022AMPAkines, BDNF, cyclic AMP, drug tolerance, glutamate, mGluR5, mRNAs, NIH, PAK (p21-activated kinase), sleep

Caffeine is the most popular smart drug in the world. With a $90,000 grant from FRAXA Research Foundation, Alberto Martire, PhD and Antonella Borreca, PhD in Rome, Italy are investigating adenosine receptors antagonists to treat Fragile X syndrome. Compounds which are able to block adenosine receptors are commonly found in tea, chocolate, and coffee.

Bryostatin Restores Learning and Memory in Adult Fragile X Mice

FRAXA Research Foundation Research Updates March 11, 2015December 26, 2019Alzheimer's, BDNF, cancer, FRAXA-DVI, GSK3, PSD-95

A bizarre marine critter found off the California coast — Bugula neritina— is the only known source of a potential new Fragile X treatment, Bryostatin. Last month, FRAXA sat down with scientists from Neurotrope BioScience, a specialty biopharmaceutical company developing medicines for rare diseases and Alzheimer’s based on Bryostatin. Their Fragile X program is based on research by a West Virginia team led by Daniel Alkon, MD, which showed that Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult Fragile X mice.

AMPAkines and BDNF in Fragile X: UCI Researchers Restore Memory Process in Fragile X

FRAXA Research Foundation 2001-2005 Grants • 2006-2010 Grants • Disease Mechanisms • Lauterborn, Julie • Research Grant Results • Treatment Targets • University of California, Irvine February 14, 2008August 5, 2021AMPA, AMPAkines, BDNF, glutamate, mGluR5, PAK (p21-activated kinase)

With a $104,498 grant from FRAXA Research Foundation from 2003-2008, Dr. Julie Lauterborn at the University of California has done several studies on dentritic spines and finding treatment targets for memory retention in Fragile X mice.

Therapeutic Interventions in FMR1 Knockout and Transgenic Mice: Role of the FMR1 Gene

FRAXA Research Foundation 1994-2000 Grants • 2001-2005 Grants • 2006-2010 Grants • Albeck, David • Baylor College of Medicine • Brennan, Francis • Completed Research Grants • Disease Mechanisms • Paylor, Richard • Treatment Targets February 13, 2006April 25, 2018AMPAkines, BDNF, PAK (p21-activated kinase), seizure, startle

With a $229,000 grant from FRAXA Research Foundation in 2006, Drs. Richard Paylor, David Albeck, and Francis Brennan at the Baylor College of Medicine found that, in mice as in humans, the level of Fragile X protein in brain cells plays a prominent role in determining levels of activity and anxiety.